The aim of this study was to examine the in vitro/in vivo relationship of the drug release behavior of a sustained-release formulation of gabapentin. The immediate-release formulation was used as the reference formulation. The dissolution test was employed using pH 1.2, 4.0, or 6.8 buffer solution, or water, to determine the in vitro release behaviors of gabapentin tablets. Gabapentin was released completely within 1 h from the immediate-release tablet and released for 12 h from the sustained-release tablet. A single dose (600 mg) of each formulation was orally administered to four beagle dogs under fasted conditions, and the pharmacokinetic parameters were calculated. Although the sustained-release tablet did not disintegrate and had slow drug release characteristics, it showed similar pharmacokinetic parameters to the immediate-release tablet, which rapidly disintegrated and showed fast drug release. Thus, the in vivo release of gabapentin did not correlate with in vitro release of drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12272-001-1246-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An investigation of the drug release kinetics of 3D-Printed two compartment Theophylline and Prednisolone tablets.
Int J Pharm
January 2025
Chair of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72074 Tuebingen, Germany. Electronic address:
Pharmaceutical 3D printing (3DP) not only offers the possibility of dose personalization but also the co-administration of multiple active pharmaceutical ingredients (APIs) in one combination tablet. In this study, Theophylline (TPH) and Prednisolone (PSL) were printed as bi-tablets, which are single tablets with two distinct separate compartments. New findings show that the combination therapy of TPH with systemic corticosteroids shows a highly synergistic effect in the treatment of pulmonary diseases.
View Article and Find Full Text PDFFirst clinical post-approval, observational study to assess clinical safety and effectiveness of brivaracetam sustained-release formulation in real-life settings of India: BEAM study.
Seizure
January 2025
Medical Affairs, Torrent Pharmaceuticals Limited, Ahmedabad, Gujarat, India.
Purpose: Brivaracetam (BRV) sustained-release (SR) tablets have recently been approved to treat focal seizures in India. SR formulations enhance patient adherence and quality of life (QoL). We assessed safety and effectiveness of BRV-SR for epilepsy management in Indian real-life settings.
View Article and Find Full Text PDFNovel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency.
PLoS One
January 2025
The National Centre of Vaccines and Bioprocessing, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Methotrexate (MTX) is classified as an antimetabolite. It's commonly used to treat lung cancer. MTX is an immunosuppressant following the above-mentioned mechanism of action due to its poor selectivity.
View Article and Find Full Text PDFA novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics.
Eur J Pharm Biopharm
February 2025
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China. Electronic address:
The narrow absorption window of levodopa and the significant impact of peripheral decarboxylase are the most limiting factors in maintaining prolonged and smooth plasma concentration in patients with Parkinson's disease (PD). Therefore, this study aims to design a novel gastroretentive carbidopa-levodopa three-layer tablet, which consists of an expansion layer, an immediate-release layer, and a sustained-release layer. The expansion layer rapidly expanded with sufficient structural strength and stayed in the beagle's stomach for more than 10 h, delineating excellent gastric retention effects.
View Article and Find Full Text PDF[Mechanism of action of Zhengqing Fengtongning Sustained-release Tablets for treatment of knee osteoarthritis based on metabolomics and intestinal flora].
Zhongguo Zhong Yao Za Zhi
December 2024
Hunan University of Chinese Medicine Changsha 410208, China Hunan Academy of Chinese Medicine Changsha 410013, China.
In order to elucidate the therapeutic effect and mechanism of action of Zhengqing Fengtongning Sustained-release Tablets on knee osteoarthritis, this study created a knee osteoarthritis model using 0.2 mL 40 g·L~(-1) papain and randomly divided the rats into the model group, high-dose and low-dose groups of Zhengqing Fengtongning Sustained-release Tablets, and celecoxib group. All groups were given the drug for four weeks, with the diameter of their knee joint being measured during this period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!